Skip to main content
NEUROTECH INTERNATIONAL LIMITED logo

NEUROTECH INTERNATIONAL LIMITED — Investor Relations & Filings

Ticker · NTI ISIN · AU000000NTI9 ASX Professional, scientific and technical activities
Open in API
Filings indexed 667 across all filing types
Latest filing 2024-01-29 Director's Dealing
Country AU Australia
Listing ASX NTI

About NEUROTECH INTERNATIONAL LIMITED

https://neurotechinternational.com/

Neurotech International Limited is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for neurodevelopmental and neurological disorders. The company specializes in neuroprotective therapies, primarily targeting pediatric conditions with significant unmet medical needs, including Autism Spectrum Disorder (ASD), Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS), and Pediatric Acute-onset Neuropsychiatric Syndrome (PANS). Its lead drug candidate, NTI164, is a proprietary, broad-spectrum cannabinoid formulation derived from a unique cannabis strain. NTI164 is engineered to exert anti-inflammatory and neuroprotective effects by modulating neuroinflammatory pathways. The company conducts clinical trials to establish the safety and efficacy of its treatments, aiming to provide transformative behavioral and functional improvements for patients.

Recent filings

Filing Released Lang Actions
Change of Director's Interest Notice 2 pages 152.8KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rules and the Corporations Act. It details a director's change in shareholding, including the number of securities held before and after the change, the nature of the transaction (on-market purchase), and dates. This matches the description of a Director's Dealing report, which involves reporting personal share transactions by company directors and executives. The document is concise and focused solely on the director's share transactions, with no financial statements or broader company information. Therefore, it fits the 'Director's Dealing' category (DIRS).
2024-01-29 English
Amended Change of Director's Interest Notice 4 pages 253.6KB
Director's Dealing Classification · 100% confidence The document is an 'Amended Appendix 3Y' which is a Change of Director's Interest Notice. It details the acquisition of shares by a director, Dr Thomas Duthy, including the number of securities held before and after the change, the nature of the change, and the date. Appendix 3Y is a standard ASX form used to notify changes in directors' interests in securities. This type of document is classified as 'Director's Dealing' (DIRS) because it reports personal share transactions by company directors. The document is about a specific director's share transactions and does not contain financial statements, earnings data, or other report types. Therefore, the correct classification is DIRS with high confidence.
2024-01-29 English
NTI Receives HREC Approval for Cerebral Palsy Trial 2 pages 188.3KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 29 January 2024 from Neurotech International Limited. It announces the receipt of Human Research Ethics Committee (HREC) approval and Therapeutic Goods Administration (TGA) clearance to commence a Phase I/II clinical trial for a drug candidate NTI164 targeting Spastic Diplegia Cerebral Palsy. The content focuses on the clinical trial details, regulatory approvals, trial design, and expected commencement date. There are no financial statements, earnings data, or management discussion of financial results. The document is a regulatory announcement about clinical trial approval and commencement, not a financial report or earnings release. It is not a report publication announcement since it contains substantive information about the trial and regulatory approvals. The document fits best under Regulatory Filings (RNS) as it is a general regulatory announcement about clinical trial approval and commencement, which does not fit other specific categories like earnings release, capital update, or management report.
2024-01-28 English
Quarterly Activities/Appendix 4C Cash Flow Report 11 pages 633.8KB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Quarterly Activities Report for the period ending 31 December 2023' and contains detailed updates on clinical trials, health economic modelling, and future outlooks for the company Neurotech International Limited. It includes substantive financial and operational data for a quarter (Q2 FY24), such as clinical trial progress, regulatory approvals, and expected milestones. The presence of an Appendix 4C Quarterly Cash Flow Report mentioned further supports that this is a quarterly report. The document is comprehensive and exceeds 5,000 characters, containing actual financial and operational data rather than just an announcement or summary. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q2 2024
2024-01-23 English
Application for quotation of securities - NTI 6 pages 28.7KB
Capital/Financing Update Classification · 95% confidence The document is an application for quotation of securities on the ASX by Neurotech International Limited. It details the number and type of securities to be quoted, issue dates, and compliance with listing rules. There is no financial performance data, earnings information, or management discussion. The document is an announcement related to capital markets activity, specifically the issuance and quotation of new shares. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes.
2024-01-21 English
Secondary Trading Notice 1 page 93.5KB
Share Issue/Capital Change Classification · 95% confidence The document is an ASX announcement dated 22 January 2024. It is titled 'Secondary Trading Notice Pursuant to Section 708A(5)(e) of the Corporations Act' and discusses the issuance of ordinary fully paid shares without disclosure under Part 6D.2 of the Corporations Act. The notice confirms compliance with relevant sections of the Corporations Act and states there is no excluded information to disclose. The document is short (2687 characters) and is a regulatory notice about share issuance without a full disclosure document. It does not contain financial statements, detailed financial data, or management discussion. It is not a report but a regulatory announcement about capital changes. Therefore, it fits best under the category of Share Issue/Capital Change (SHA).
2024-01-21 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.